Search

Search Bar
01/01/2023 Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
García-Calderón C.B., Sierro-Martínez B., García-Guerrero E., Sanoja-Flores L., Muñoz-García R., Ruiz-Maldonado V., Jimenez-Leon M.R., Delgado-Serrano J., Molinos-Quintana Á., Guijarro-Albaladejo B., Carrasco-Brocal I., Lucena J.-M., García-Lozano J.-R., Blázquez-Goñi C., Reguera-Ortega J.L., González-Escribano M.-F., Reinoso-Segura M., Briones J., Pérez-Simón J.A., Caballero-Velázquez T.. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1152498. PMID:37122702. IF:5.700(Q1/3D).
01/12/2022 mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients (Nov, 10.1007/s00520-022-07376-w, 2022)
Albiol, N, Aso, O, Gomez-Perez, L, Triquell, M, Roch, N, Lazaro, E, Esquirol, A, Gonzalez, I, Lopez-Contreras, J, Sierra, J, Martino, R, Garcia-Cadenas, I. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients (Nov, 10.1007/s00520-022-07376-w, 2022). SUPPORTIVE CARE IN CANCER. 2022; 30(12)DOI:10.1007/s00520-022-07452-1. PMID:36400980. IF:3.100(Q1/3D).
01/10/2022 Identification of Two Eosinophil Subsets in Induced Sputum from Patients with Allergic Asthma According to CD15 and CD66b Expression
Curto, E, Mateus-Medina, EF, Crespo-Lessmann, A, Osuna-Gomez, R, Ujaldon-Miro, C, Garcia-Moral, A, Galvan-Blasco, P, Soto-Retes, L, Ramos-Barbon, D, Plaza, V. Identification of Two Eosinophil Subsets in Induced Sputum from Patients with Allergic Asthma According to CD15 and CD66b Expression. International Journal of Environmental Research and Public Health. 2022; 19(20)DOI:10.3390/ijerph192013400. PMID:36293979. IF:4.614(Q1/3D).
01/10/2022 Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
Saliba, RM, Alousi, AM, Pidala, J, Arora, M, Spellman, SR, Hemmer, MT, Wang, T, Abboud, C, Ahmed, S, Antin, JH, Beitinjaneh, A, Buchbinder, D, Byrne, M, Cahn, JY, Choe, H, Hanna, R, Hematti, P, Kamble, RT, Kitko, CL, Laughlin, M, Lekakis, L, MacMillan, ML, Martino, R, Mehta, PA, Nishihori, T, Patel, SS, Perales, MA, Rangarajan, HG, Ringden, O, Rosenthal, J, Savani, BN, Schultz, KR, Seo, S, Teshima, T, van der Poel, M, Verdonck, LF, Weisdorf, D, Wirk, B, Yared, JA, Schriber, J, Champlin, RE, Ciurea, SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation And Cellular Therapy. 2022; 28(10)DOI:10.1016/j.jtct.2022.07.013. PMID:35853610. IF:3.200(Q2/5D).